Published in Eur J Cancer on March 01, 1979
Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) (1982) 1.80
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat (1983) 0.82
[Estrogen and androgen receptors in patients with acne vulgaris (author's transl)]. Arch Dermatol Res (1980) 0.75
Analysis by DNA polymerase alpha activity of human breast tumour proliferation and the effect of endocrine therapy. Br J Cancer (1990) 0.75
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) (1981) 2.14
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol (1991) 1.83
Oestrogen receptors and prognosis in early breast cancer. Lancet (1979) 1.83
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 1.62
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 1.53
Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: results of a case-control study. Eur J Cancer (1995) 1.52
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett (2005) 1.50
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
A randomized controlled trial of penicillin vs clindamycin for the treatment of aspiration pneumonia in children. Arch Pediatr Adolesc Med (1997) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat (2005) 1.41
Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med (2009) 1.40
Prostate-specific antigen: problems in analysis. Eur J Cancer (1991) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
Metabolism of C19-steroids by foetal cotyledons from the bovine placenta at term. Res Vet Sci (1969) 1.32
Steroid metabolism by human breast tumours. Biochem J (1970) 1.32
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer (1986) 1.30
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology (2003) 1.29
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer (1994) 1.25
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer (1986) 1.24
Plasma 17OH-progesterone concentrations in newborn infants. Arch Dis Child (1979) 1.24
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer (1987) 1.23
Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate (1997) 1.23
Identification of talc on surgeons' gloves and in tissue from starch granulomas. Br J Surg (1975) 1.22
Plasma prolactin in breast cancer. Eur J Cancer (1973) 1.22
Ingestion of talc particles by cultured lung fibroblasts. Environ Res (1975) 1.22
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer (1979) 1.22
Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol (1995) 1.21
Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab (2004) 1.21
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer (2006) 1.20
The inhibition of deoxyribonucleic acid nucleotidyltransferase by stilboestrol derivatives. Biochem J (1968) 1.20
An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol (1999) 1.20
Internal quality control in clinical chemistry: a teaching review. Stat Med (1987) 1.19
Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer (2005) 1.19
Endocrine treatment in prostate cancer. Semin Surg Oncol (2000) 1.18
A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int Neuropsychol Soc (1997) 1.17
Enhanced peripheral vasodilation in humans after a fatty meal. J Am Coll Cardiol (2000) 1.16
Talc and carcinoma of the ovary and cervix. J Obstet Gynaecol Br Commonw (1971) 1.15
E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer (2001) 1.15
Shipping stress and social status effects on pig performance, plasma cortisol, natural killer cell activity, and leukocyte numbers. J Anim Sci (1993) 1.15
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol (2009) 1.12
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer (2005) 1.12
Survival patterns in hormone treated advanced breast cancer. Br J Surg (1986) 1.12
The benefits of a shared-care prostate clinic. Br J Urol (1996) 1.12
A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl (1990) 1.11
Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh) (1976) 1.10
Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer (1992) 1.10
Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol (1976) 1.10
Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. Br J Cancer (1989) 1.09
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol (1988) 1.09
Steroids in saliva for assessing endocrine function. Endocr Rev (1982) 1.09
The effect of some stilboestrol compounds on DNA polymerase from human prostatic tissue. Steroids (1970) 1.09
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol (1992) 1.09
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol (1989) 1.08
An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol (1991) 1.08
TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer (2001) 1.07
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer (1990) 1.07
Stromal cells in haemopoiesis. Ciba Found Symp (1990) 1.07